Ubidecarenone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ubidecarenone
Accession Number
DB09270
Type
Small Molecule
Groups
Experimental
Description

Ubidecarenone, also known as Coenzyme Q10, is a 1,4-benzoquinone, where Q refers to the quinone chemical group, and 10 refers to the number of isoprenyl chemical subunits in its tail. This oil-soluble, vitamin-like substance is present in most eukaryotic cells, primarily in the mitochondria. It is a component of the electron transport chain and participates in aerobic cellular respiration, generating energy in the form of ATP. Ninety-five percent of the human body’s energy is generated this way. Therefore, those organs with the highest energy requirements—such as the heart, liver and kidney—have the highest CoQ10 concentrations. There are three redox states of CoQ10: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and fully reduced (ubiquinol). The capacity of this molecule to exist in a completely oxidized form and a completely reduced form enables it to perform its functions in the electron transport chain, and as an antioxidant, respectively.

Structure
Thumb
Synonyms
  • Coenzyme Q-10
  • Coenzyme Q10
External IDs
API 31510 / API-31510 / NSC-140865
Product Ingredients
IngredientUNIICASInChI Key
Coenzyme q10, (2z)-U705VLF0VW65085-29-2ACTIUHUUMQJHFO-LLOLQPSSSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Co-enzyme Q-10 CapsulesCapsule30 mgOralAshbury Research CorporationNot applicableNot applicableCanada
Co-q10 (ubiquinone)Capsule60 mgOralAbundance Naturally LtdNot applicableNot applicableCanada
Q-gel Coenzyme Q10Capsule15 mgOralT & T Nutrition Inc.Not applicableNot applicableCanada
Watkins Coq10Tablet60 mgOralWatkins IncorporatedNot applicableNot applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acti-ubiquinone 50 Cap 50mgCapsule50 mgOralActi Form Ltd.1991-12-312005-03-21Canada
Biogard Ubiquinone Cap 30mgCapsule30 mgOralSisu Inc.1994-12-312001-08-01Canada
Biomed Co Q 10Capsule100 mgOralSisu Inc.1998-02-112008-07-25Canada
Cell Tech Coenzyme Q10 - Cap 30mgCapsule30 mgOralCell Tech1996-11-122000-10-05Canada
Cellsparc 360Capsule60 mgOralAim International, Inc.1998-07-292008-09-03Canada
Co Q 10 - 50mg CapCapsule50 mgOralAlbi Naturals1994-12-312008-07-17Canada
Co-enzyme Q-10Capsule30 mgOralHolista Health (Canada) Inc.1996-12-312002-08-06Canada
Co-enzyme Q-10Capsule30 mgOralSeroyal International Inc.1995-12-312008-07-14Canada
Co-enzyme Q10 100mgCapsule100 mgOralNatural Factors Nutritional Products Ltd.1999-07-122009-09-28Canada
Co-enzyme Q10 30mg CapsulesCapsule30 mgOralAlive Vitamins1998-07-272005-07-04Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BiosculptUbidecarenone (1.5 mg) + Choline bitartrate (0.3 mg) + Chromium (40 mcg) + Inositol (0.3 mg) + Calcium pantothenate (60 mg) + Pyridoxine hydrochloride (4 mg)SolutionOralMaxion Nutrition Corp.2002-06-102004-07-20Canada
Co-q10 and Vitamin EUbidecarenone (100 mg) + Vitamin E (300 unit)CapsuleOralBiomed International Products Corp.2003-10-012006-06-29Canada
Coenzyme Q10 Isotonix Vitamin and Mineral SupplementUbidecarenone (30.03 mg) + Potassium (32.43 mg) + Riboflavin (0.9 mg) + Vitamin E (60.06 mg)PowderOralMarket America2002-06-042008-09-04Canada
Daily Supplement PacksUbidecarenone (30 mg) + Cyanocobalamin (125 mcg) + Folic Acid (0.4 mg) + Magnesium (150 mg) + Pyridoxine (50 mg) + Vitamin E (400 unit)CapsuleOralWn Pharmaceuticals Ltd.2002-10-182005-08-15Canada
Formula BUbidecarenone (30 mg) + Magnesium (200 mg) + Pyridoxine (25 mg) + Thiamine (25 mg) + Vitamin C (250 mg) + Zinc (30 mg)CapsuleOralBalance Plus, Inc.2000-04-192004-08-17Canada
Formula DprUbidecarenone (30 mg) + Riboflavin (30 mg)CapsuleOralBalance Plus, Inc.2000-03-082004-08-17Canada
Formula Statin SupportUbidecarenone (30 mg) + Cyanocobalamin (50 mcg) + Magnesium (200 mg) + Pantothenic acid (50 mg) + Pyridoxine (50 mg)CapsuleOralBalance Plus, Inc.2000-04-192004-08-17Canada
L.I.P. ComplexUbidecarenone (10 mg) + Beta carotene (625 unit) + Cholecalciferol (200 unit) + Chromium (200 mcg) + Cyanocobalamin (50 mcg) + Folic Acid (0.4 mg) + Magnesium (50 mg) + Pyridoxine hydrochloride (50 mg) + Vitamin A palmitate (1875 unit) + Calcium ascorbate (100 mg) + Vitamin E (75 unit)TabletOralAbundance Marketing Ltd.2000-12-062004-06-30Canada
N.E.U. ComplexUbidecarenone (10 mg) + Cholecalciferol (400 unit) + Cyanocobalamin (50 mcg) + Folic Acid (0.4 mg) + Nicotinamide (25 mg) + Pyridoxine hydrochloride (10 mg) + Riboflavin (10 mg) + Thiamine Hydrochloride (10 mg) + Calcium ascorbate (150 mg) + Vitamin E (60 unit)TabletOralAbundance Marketing Ltd.2000-12-042004-06-30Canada
N.U.T. ComplexUbidecarenone (10 mg) + Chromium (200 mcg) + Cyanocobalamin (50 mcg) + Folic Acid (0.4 mg) + Magnesium (100 mg) + Manganese (5 mg) + Potassium (50 mg) + Pyridoxine hydrochloride (15 mg) + Calcium ascorbate (100 mg) + Zinc (10 mg)TabletOralAbundance Marketing Ltd.2000-12-062004-06-30Canada
Categories
UNII
EJ27X76M46
CAS number
303-98-0
Weight
Average: 863.3435
Monoisotopic: 862.683911368
Chemical Formula
C59H90O4
InChI Key
ACTIUHUUMQJHFO-UPTCCGCDSA-N
InChI
InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
IUPAC Name
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
SMILES
COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Acute oral LD50 (rat) – greater than 4,000 mg/Kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe risk or severity of adverse effects can be increased when Abafungin is combined with Ubidecarenone.Investigational
AcenocoumarolUbidecarenone may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Ubidecarenone can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe serum concentration of Ubidecarenone can be increased when it is combined with Acetazolamide.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Ubidecarenone.Approved
AlbaconazoleThe risk or severity of adverse effects can be increased when Albaconazole is combined with Ubidecarenone.Investigational
AldesleukinThe serum concentration of Ubidecarenone can be increased when it is combined with Aldesleukin.Approved
AlgeldrateThe serum concentration of Ubidecarenone can be decreased when it is combined with Algeldrate.Experimental
AlmagateThe serum concentration of Ubidecarenone can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Ubidecarenone can be decreased when it is combined with Almasilate.Experimental
AloglutamolThe serum concentration of Ubidecarenone can be decreased when it is combined with Aloglutamol.Experimental
AlprazolamThe serum concentration of Ubidecarenone can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AluminiumThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminum hydroxide.Approved
AmbroxolThe serum concentration of Ubidecarenone can be increased when it is combined with Ambroxol.Approved
AmiodaroneThe metabolism of Ubidecarenone can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Ubidecarenone can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Ubidecarenone can be increased when it is combined with Amprenavir.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Ubidecarenone.Approved
AnastrozoleThe serum concentration of Ubidecarenone can be increased when it is combined with Anastrozole.Approved, Investigational
AntipyrineThe serum concentration of Ubidecarenone can be increased when it is combined with Antipyrine.Approved
AprepitantThe serum concentration of Ubidecarenone can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Ubidecarenone can be increased when it is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Ubidecarenone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Ubidecarenone can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Ubidecarenone can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Ubidecarenone can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Ubidecarenone can be increased when it is combined with Azelastine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Ubidecarenone.Approved
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Ubidecarenone.Investigational
AzithromycinThe serum concentration of Ubidecarenone can be increased when it is combined with Azithromycin.Approved
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Ubidecarenone.Approved
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Ubidecarenone.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Ubidecarenone.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Ubidecarenone.Approved, Withdrawn
BetamethasoneThe serum concentration of Ubidecarenone can be increased when it is combined with Betamethasone.Approved, Vet Approved
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Ubidecarenone.Approved
BicalutamideThe serum concentration of Ubidecarenone can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Bifonazole.Approved
Bismuth SubcitrateThe serum concentration of Ubidecarenone can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Ubidecarenone can be decreased when it is combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Ubidecarenone can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe serum concentration of Ubidecarenone can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Ubidecarenone can be increased when combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe serum concentration of Ubidecarenone can be increased when it is combined with Brentuximab vedotin.Approved
BromocriptineThe serum concentration of Ubidecarenone can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Ubidecarenone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Ubidecarenone.Approved
CabergolineThe serum concentration of Ubidecarenone can be increased when it is combined with Cabergoline.Approved
CaffeineThe serum concentration of Ubidecarenone can be increased when it is combined with Caffeine.Approved
Calcium CarbonateThe serum concentration of Ubidecarenone can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Ubidecarenone can be decreased when it is combined with Calcium silicate.Experimental
CapsaicinThe serum concentration of Ubidecarenone can be increased when it is combined with Capsaicin.Approved
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Ubidecarenone.Vet Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Ubidecarenone.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Ubidecarenone.Experimental
CaspofunginThe serum concentration of Ubidecarenone can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Ubidecarenone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Ubidecarenone can be increased when it is combined with Cerivastatin.Withdrawn
ChloramphenicolThe serum concentration of Ubidecarenone can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Ubidecarenone can be increased when it is combined with Chlorzoxazone.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Ubidecarenone.Approved
CilostazolThe serum concentration of Ubidecarenone can be increased when it is combined with Cilostazol.Approved
CimetidineThe serum concentration of Ubidecarenone can be increased when it is combined with Cimetidine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Ubidecarenone.Approved
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Ubidecarenone.Approved
CiprofloxacinThe serum concentration of Ubidecarenone can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Ubidecarenone can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Ubidecarenone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Ubidecarenone can be increased when it is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Ubidecarenone.Approved
ClindamycinThe serum concentration of Ubidecarenone can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe serum concentration of Ubidecarenone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Ubidecarenone can be increased when it is combined with Clomifene.Approved, Investigational
ClorindioneUbidecarenone may decrease the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe serum concentration of Ubidecarenone can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Ubidecarenone can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Ubidecarenone can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Ubidecarenone can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Ubidecarenone.Approved
ConivaptanThe serum concentration of Ubidecarenone can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe serum concentration of Ubidecarenone can be increased when it is combined with Cortisone acetate.Approved
CrizotinibThe serum concentration of Ubidecarenone can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Ubidecarenone can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Ubidecarenone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Ubidecarenone can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DaclatasvirThe serum concentration of Ubidecarenone can be increased when it is combined with Daclatasvir.Approved
DalfopristinThe serum concentration of Ubidecarenone can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Ubidecarenone can be increased when it is combined with Danazol.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Ubidecarenone is combined with Daptomycin.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Ubidecarenone.Experimental
DarunavirThe serum concentration of Ubidecarenone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ubidecarenone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Ubidecarenone can be increased when it is combined with Daunorubicin.Approved
DelavirdineThe serum concentration of Ubidecarenone can be increased when it is combined with Delavirdine.Approved
DesipramineThe serum concentration of Ubidecarenone can be increased when it is combined with Desipramine.Approved
DexamethasoneThe serum concentration of Ubidecarenone can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextropropoxypheneThe serum concentration of Ubidecarenone can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Ubidecarenone can be increased when it is combined with Diazepam.Approved, Illicit, Vet Approved
DicoumarolUbidecarenone may decrease the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Ubidecarenone can be increased when it is combined with Diethylstilbestrol.Approved
DihydroergotamineThe serum concentration of Ubidecarenone can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Ubidecarenone can be increased when it is combined with Diltiazem.Approved
Dimethyl sulfoxideThe serum concentration of Ubidecarenone can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DiphenadioneUbidecarenone may decrease the anticoagulant activities of Diphenadione.Experimental
DocetaxelThe serum concentration of Ubidecarenone can be increased when it is combined with Docetaxel.Approved, Investigational
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Ubidecarenone.Investigational
DoxorubicinThe serum concentration of Ubidecarenone can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Ubidecarenone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Ubidecarenone can be increased when it is combined with Dronedarone.Approved
EconazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Econazole.Approved
EfavirenzThe serum concentration of Ubidecarenone can be increased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Ubidecarenone.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Ubidecarenone.Approved
ElbasvirThe serum concentration of Ubidecarenone can be increased when it is combined with Elbasvir.Approved
EnasidenibThe serum concentration of Ubidecarenone can be increased when it is combined with Enasidenib.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Ubidecarenone.Approved, Investigational
EpinephrineThe serum concentration of Ubidecarenone can be increased when it is combined with Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe serum concentration of Ubidecarenone can be increased when it is combined with Ergoloid mesylate.Approved
ErgonovineThe serum concentration of Ubidecarenone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Ubidecarenone can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Ubidecarenone can be increased when it is combined with Erythromycin.Approved, Vet Approved
EthanolThe serum concentration of Ubidecarenone can be increased when it is combined with Ethanol.Approved
Ethyl biscoumacetateUbidecarenone may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtoposideThe serum concentration of Ubidecarenone can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Ubidecarenone can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Ubidecarenone can be decreased when it is combined with Etravirine.Approved
EzetimibeThe serum concentration of Ubidecarenone can be increased when it is combined with Ezetimibe.Approved
FelodipineThe serum concentration of Ubidecarenone can be increased when it is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Ubidecarenone.Withdrawn
FenofibrateThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Ubidecarenone.Approved
FentanylThe serum concentration of Ubidecarenone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Ubidecarenone.Experimental
FidaxomicinThe risk or severity of adverse effects can be increased when Fidaxomicin is combined with Ubidecarenone.Approved
FluconazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Fluconazole.Approved
FluindioneUbidecarenone may decrease the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ubidecarenone.Approved
FluoxetineThe serum concentration of Ubidecarenone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
Fluticasone propionateThe serum concentration of Ubidecarenone can be increased when it is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Ubidecarenone can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Ubidecarenone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Ubidecarenone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ubidecarenone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Ubidecarenone can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe risk or severity of adverse effects can be increased when Fusidic Acid is combined with Ubidecarenone.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ubidecarenone.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Ubidecarenone.Investigational
GemfibrozilThe serum concentration of Ubidecarenone can be increased when it is combined with Gemfibrozil.Approved
GlyburideThe serum concentration of Ubidecarenone can be increased when it is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe serum concentration of Ubidecarenone can be increased when it is combined with Glycerol Phenylbutyrate.Approved
HaloperidolThe serum concentration of Ubidecarenone can be increased when it is combined with Haloperidol.Approved
HistamineThe serum concentration of Ubidecarenone can be increased when it is combined with Histamine.Approved, Investigational
HydralazineThe serum concentration of Ubidecarenone can be increased when it is combined with Hydralazine.Approved
HydrocortisoneThe serum concentration of Ubidecarenone can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydrotalciteThe serum concentration of Ubidecarenone can be decreased when it is combined with Hydrotalcite.Experimental
IdelalisibThe serum concentration of Ubidecarenone can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ubidecarenone can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Ubidecarenone can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Ubidecarenone can be increased when it is combined with Imatinib.Approved
IndinavirThe serum concentration of Ubidecarenone can be increased when it is combined with Indinavir.Approved
indisulamThe serum concentration of Ubidecarenone can be increased when it is combined with indisulam.Investigational
IrbesartanThe serum concentration of Ubidecarenone can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Ubidecarenone can be increased when it is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe risk or severity of adverse effects can be increased when Isavuconazole is combined with Ubidecarenone.Approved
IsavuconazoniumThe serum concentration of Ubidecarenone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Ubidecarenone.Approved
IsoniazidThe serum concentration of Ubidecarenone can be increased when it is combined with Isoniazid.Approved
IsradipineThe serum concentration of Ubidecarenone can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ubidecarenone can be increased when it is combined with Ivacaftor.Approved
JosamycinThe serum concentration of Ubidecarenone can be increased when it is combined with Josamycin.Approved
KetazolamThe serum concentration of Ubidecarenone can be increased when it is combined with Ketazolam.Approved
KetoconazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Ubidecarenone.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Ubidecarenone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ubidecarenone.Approved, Investigational
LansoprazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Ubidecarenone.Approved
LapatinibThe serum concentration of Ubidecarenone can be increased when it is combined with Lapatinib.Approved, Investigational
LercanidipineThe serum concentration of Ubidecarenone can be increased when it is combined with Lercanidipine.Approved, Investigational
LevofloxacinThe serum concentration of Ubidecarenone can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe serum concentration of Ubidecarenone can be increased when it is combined with Levosalbutamol.Approved
LidocaineThe serum concentration of Ubidecarenone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Ubidecarenone.Experimental
LinagliptinThe serum concentration of Ubidecarenone can be increased when it is combined with Linagliptin.Approved
LomitapideThe serum concentration of Ubidecarenone can be increased when it is combined with Lomitapide.Approved
LomustineThe serum concentration of Ubidecarenone can be increased when it is combined with Lomustine.Approved
LopinavirThe serum concentration of Ubidecarenone can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Ubidecarenone can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Ubidecarenone can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Ubidecarenone can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Luliconazole.Approved
LurasidoneThe serum concentration of Ubidecarenone can be increased when it is combined with Lurasidone.Approved
MagaldrateThe serum concentration of Ubidecarenone can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium HydroxideThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium silicate.Experimental
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Ubidecarenone.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe serum concentration of Ubidecarenone can be increased when it is combined with Manidipine.Approved
MefloquineThe serum concentration of Ubidecarenone can be increased when it is combined with Mefloquine.Approved
MequitazineThe serum concentration of Ubidecarenone can be increased when it is combined with Mequitazine.Approved
MethadoneThe serum concentration of Ubidecarenone can be increased when it is combined with Methadone.Approved
MethazolamideThe serum concentration of Ubidecarenone can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Methimazole.Approved
MethylergometrineThe serum concentration of Ubidecarenone can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe serum concentration of Ubidecarenone can be increased when it is combined with Methylprednisolone.Approved, Vet Approved
MetronidazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Metronidazole.Approved
MetyraponeThe serum concentration of Ubidecarenone can be increased when it is combined with Metyrapone.Approved
MibefradilThe serum concentration of Ubidecarenone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Ubidecarenone can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Ubidecarenone can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe serum concentration of Ubidecarenone can be increased when it is combined with Mirtazapine.Approved
MitoxantroneThe serum concentration of Ubidecarenone can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Ubidecarenone can be increased when it is combined with Modafinil.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Ubidecarenone.Investigational
NefazodoneThe serum concentration of Ubidecarenone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ubidecarenone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ubidecarenone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Ubidecarenone can be increased when it is combined with Nevirapine.Approved
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
NicardipineThe serum concentration of Ubidecarenone can be increased when it is combined with Nicardipine.Approved
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Ubidecarenone.Approved
NifedipineThe serum concentration of Ubidecarenone can be increased when it is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Ubidecarenone.Experimental
NilotinibThe serum concentration of Ubidecarenone can be increased when it is combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Ubidecarenone.Experimental
NilvadipineThe serum concentration of Ubidecarenone can be increased when it is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ubidecarenone.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Ubidecarenone.Approved
NisoldipineThe serum concentration of Ubidecarenone can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Ubidecarenone can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe serum concentration of Ubidecarenone can be increased when it is combined with Nitric Oxide.Approved
NorfloxacinThe serum concentration of Ubidecarenone can be increased when it is combined with Norfloxacin.Approved
NoscapineThe serum concentration of Ubidecarenone can be increased when it is combined with Noscapine.Investigational
OlanzapineThe serum concentration of Ubidecarenone can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Ubidecarenone can be increased when it is combined with Olaparib.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Ubidecarenone.Vet Approved
OmeprazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Ubidecarenone.Experimental
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Ubidecarenone.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Ubidecarenone.Approved
OxybutyninThe serum concentration of Ubidecarenone can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Ubidecarenone can be increased when it is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe serum concentration of Ubidecarenone can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Ubidecarenone can be increased when it is combined with Palbociclib.Approved
ParamethasoneThe serum concentration of Ubidecarenone can be increased when it is combined with Paramethasone.Approved
PazopanibUbidecarenone may increase the hepatotoxic activities of Pazopanib.Approved
PergolideThe serum concentration of Ubidecarenone can be increased when it is combined with Pergolide.Approved, Vet Approved, Withdrawn
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Ubidecarenone.Approved
PhenelzineThe serum concentration of Ubidecarenone can be increased when it is combined with Phenelzine.Approved
PhenindioneUbidecarenone may decrease the anticoagulant activities of Phenindione.Approved
PhenprocoumonUbidecarenone may decrease the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Ubidecarenone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Ubidecarenone can be increased when it is combined with Pilocarpine.Approved
PimozideThe serum concentration of Ubidecarenone can be increased when it is combined with Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Ubidecarenone.Approved
PosaconazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Ubidecarenone can be increased when it is combined with Pravastatin.Approved
PrednisoloneThe serum concentration of Ubidecarenone can be increased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Ubidecarenone can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ubidecarenone.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Ubidecarenone.Withdrawn
PrimaquineThe serum concentration of Ubidecarenone can be increased when it is combined with Primaquine.Approved
ProgesteroneThe serum concentration of Ubidecarenone can be increased when it is combined with Progesterone.Approved, Vet Approved
PropofolThe serum concentration of Ubidecarenone can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
QuinidineThe serum concentration of Ubidecarenone can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Ubidecarenone can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Ubidecarenone can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Ubidecarenone can be increased when it is combined with Raloxifene.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Ubidecarenone.Approved
RanitidineThe serum concentration of Ubidecarenone can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ubidecarenone can be increased when it is combined with Ranolazine.Approved, Investigational
RavuconazoleThe risk or severity of adverse effects can be increased when Ravuconazole is combined with Ubidecarenone.Investigational
RegorafenibThe serum concentration of Ubidecarenone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Ubidecarenone can be increased when it is combined with Repaglinide.Approved, Investigational
ResveratrolThe serum concentration of Ubidecarenone can be increased when it is combined with Resveratrol.Experimental, Investigational
RifabutinThe serum concentration of Ubidecarenone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Ubidecarenone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ubidecarenone can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Ubidecarenone can be increased when it is combined with Rilpivirine.Approved
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Ubidecarenone.Approved, Investigational
RisperidoneThe serum concentration of Ubidecarenone can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Ubidecarenone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of Ubidecarenone can be increased when it is combined with Rivastigmine.Approved, Investigational
RolitetracyclineThe serum concentration of Ubidecarenone can be increased when it is combined with Rolitetracycline.Approved
RosuvastatinThe serum concentration of Ubidecarenone can be increased when it is combined with Rosuvastatin.Approved
RoxithromycinThe serum concentration of Ubidecarenone can be increased when it is combined with Roxithromycin.Approved, Withdrawn
RutinThe serum concentration of Ubidecarenone can be increased when it is combined with Rutin.Experimental
SalbutamolThe serum concentration of Ubidecarenone can be increased when it is combined with Salbutamol.Approved, Vet Approved
SaquinavirThe serum concentration of Ubidecarenone can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe serum concentration of Ubidecarenone can be increased when it is combined with Sarilumab.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Ubidecarenone.Approved
SertralineThe serum concentration of Ubidecarenone can be increased when it is combined with Sertraline.Approved
SildenafilThe serum concentration of Ubidecarenone can be increased when it is combined with Sildenafil.Approved, Investigational
SimeprevirThe serum concentration of Ubidecarenone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Ubidecarenone can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Ubidecarenone can be increased when it is combined with Sirolimus.Approved, Investigational
SitaxentanThe serum concentration of Ubidecarenone can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Ubidecarenone.Investigational
SorafenibThe serum concentration of Ubidecarenone can be increased when it is combined with Sorafenib.Approved, Investigational
SpiramycinThe risk or severity of adverse effects can be increased when Spiramycin is combined with Ubidecarenone.Approved
St. John's WortThe metabolism of Ubidecarenone can be increased when combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ubidecarenone can be increased when it is combined with Stiripentol.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Ubidecarenone.Approved
SulfamethoxazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Sulfamethoxazole.Approved
SulfanilamideThe serum concentration of Ubidecarenone can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe serum concentration of Ubidecarenone can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Ubidecarenone can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilThe serum concentration of Ubidecarenone can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe serum concentration of Ubidecarenone can be increased when it is combined with Tamoxifen.Approved
TelaprevirThe serum concentration of Ubidecarenone can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Ubidecarenone can be increased when it is combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Ubidecarenone can be increased when it is combined with Temsirolimus.Approved
TeniposideThe serum concentration of Ubidecarenone can be increased when it is combined with Teniposide.Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Ubidecarenone.Approved
TerfenadineThe serum concentration of Ubidecarenone can be increased when it is combined with Terfenadine.Withdrawn
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Ubidecarenone.Experimental
TesmilifeneThe serum concentration of Ubidecarenone can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Ubidecarenone can be increased when it is combined with Testosterone.Approved, Investigational
TetracyclineThe serum concentration of Ubidecarenone can be increased when it is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ubidecarenone.Investigational
ThiopentalThe serum concentration of Ubidecarenone can be increased when it is combined with Thiopental.Approved, Vet Approved
TicagrelorThe serum concentration of Ubidecarenone can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Ubidecarenone can be increased when it is combined with Ticlopidine.Approved
TioclomarolUbidecarenone may decrease the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Ubidecarenone can be increased when it is combined with Tipranavir.Approved, Investigational
TofisopamThe serum concentration of Ubidecarenone can be increased when it is combined with Tofisopam.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ubidecarenone.Approved
TopiroxostatThe serum concentration of Ubidecarenone can be increased when it is combined with Topiroxostat.Approved
TopotecanThe serum concentration of Ubidecarenone can be increased when it is combined with Topotecan.Approved, Investigational
TrabectedinUbidecarenone may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TramadolThe serum concentration of Ubidecarenone can be increased when it is combined with Tramadol.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Ubidecarenone.Approved, Investigational
TranylcypromineThe serum concentration of Ubidecarenone can be increased when it is combined with Tranylcypromine.Approved
TroglitazoneThe serum concentration of Ubidecarenone can be increased when it is combined with Troglitazone.Withdrawn
TroleandomycinThe serum concentration of Ubidecarenone can be increased when it is combined with Troleandomycin.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Ubidecarenone.Vet Approved
Valproic AcidThe serum concentration of Ubidecarenone can be increased when it is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe serum concentration of Ubidecarenone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Ubidecarenone can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Ubidecarenone can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Ubidecarenone can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Ubidecarenone can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Ubidecarenone.Investigational
VoriconazoleThe serum concentration of Ubidecarenone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinUbidecarenone may decrease the anticoagulant activities of Warfarin.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Ubidecarenone.Approved
ZafirlukastThe serum concentration of Ubidecarenone can be increased when it is combined with Zafirlukast.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ubidecarenone.Approved
ZiprasidoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ziprasidone.Approved
ZucapsaicinThe serum concentration of Ubidecarenone can be increased when it is combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

General References
  1. Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995 May 24;1271(1):195-204. [PubMed:7599208]
External Links
Human Metabolome Database
HMDB01072
KEGG Drug
D01065
KEGG Compound
C11378
PubChem Compound
5281915
PubChem Substance
310265165
ChemSpider
4445197
ChEBI
46245
ChEMBL
CHEMBL454801
HET
U10
Wikipedia
Coenzyme_Q10
ATC Codes
C01EB09 — Ubidecarenone
AHFS Codes
  • 88:29.00* — Minerals
  • 88:28.00 — Multivitamin Preparations
  • 88:30.00* — Other Nutritional Agents
  • 88:20.00 — Vitamin E
  • 88:28.01* — Vitamins & Minerals
PDB Entries
1aig / 1aij / 1bcc / 1ds8 / 1dv3 / 1dv6 / 1e14 / 1e6d / 1f6n / 1fnp
show 93 more
MSDS
Download (92.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingSupportive CareCancer, Breast1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedSupportive CareSporadic Ataxia1
1, 2CompletedSupportive CareCharcot Marie Tooth Disease1
1, 2CompletedTreatmentSquamous Cell Carcinoma (SCC)1
1, 2Not Yet RecruitingSupportive CareQuality of Life1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's Disease1
2CompletedTreatmentCardiac Arrest / Sudden Cardiac Arrest1
2CompletedTreatmentHuntington's Disease (HD)1
2CompletedTreatmentMuscular Dystrophy, Duchenne1
2CompletedTreatmentNon-Proliferative Diabetic Retinopathy / Type 2 Diabetes Mellitus1
2CompletedTreatmentParkinson's Disease (PD)2
2CompletedTreatmentProgressive Supranuclear Palsy (PSP)1
2CompletedTreatmentSuperficial Basal Cell Carcinoma1
2Not Yet RecruitingTreatmentHeart Failure, Diastolic1
2Not Yet RecruitingTreatmentHeart Failure, Unspecified1
2RecruitingTreatmentMalignant Neoplasm of Pancreas1
2WithdrawnNot AvailableBipolar Affective Disorders / Depressive State1
2WithdrawnTreatmentSquamous Cell Carcinoma (SCC)1
2, 3CompletedTreatmentAtypical Parkinsonism / Progressive Supranuclear Palsy (PSP)1
2, 3CompletedTreatmentNeurological Disorders / Progressive Supranuclear Palsy (PSP)1
2, 3Enrolling by InvitationTreatmentBecker's Muscular Dystrophy (BMD) / Duchenne's Muscular Dystrophy (DMD) / Limb Girdle Muscular Dystrophy1
3TerminatedTreatmentHuntington's Disease (HD)1
4CompletedTreatmentChronic Renal Failure (CRF) / Hemodialysis-dependent patients1
4CompletedTreatmentCongestive Cardiomyopathy1
4CompletedTreatmentMuscle Soreness / Muscle Weakness / Side Effects of Statins1
4Not Yet RecruitingTreatmentIdiopathic Infertility1
Not AvailableCompletedBasic ScienceDepression, Bipolar2
Not AvailableCompletedTreatmentPolycystic Ovaries Syndrome1
Not AvailableNot Yet RecruitingTreatmentOral Aphthous Ulcer1
Not AvailableUnknown StatusBasic ScienceStatin Myopathy1
Not AvailableUnknown StatusTreatmentCoenzyme Q10 on Athero-thrombosis in APS Patients1
Not AvailableUnknown StatusTreatmentCongestive Heart Failure (CHF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral50 mg
CapsuleOral100 mg
SolutionOral
TabletOral10 mg
CapsuleOral50.0 mg
CapsuleOral12 mg
TabletOral100 mg
CapsuleOral60 mg
CapsuleOral80 mg
CapsuleOral15 mg
CapsuleOral30 mg
PowderOral
CapsuleOral10 mg
TabletOral
CapsuleOral
TabletOral60 mg
CapsuleOral25 mg
CapsuleOral20 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)50-52MSDS
water solubilityInsolubleMSDS
Predicted Properties
PropertyValueSource
Water Solubility0.000193 mg/mLALOGPS
logP9.94ALOGPS
logP17.16ChemAxon
logS-6.6ALOGPS
pKa (Strongest Basic)-4.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count31ChemAxon
Refractivity286.61 m3·mol-1ChemAxon
Polarizability112.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dj-0211112090-13e67655f61e48a95d91
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kb-0859598220-67d1d2437197bf4977c9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-014j-1132229710-87eed3c798b1c43399ec
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-0000000090-68b5c91d1736a6033778
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-08fs-0100000390-3f2c6d6cc684a14c6586
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000b-8100000890-af49da707a25798624ae

Taxonomy

Description
This compound belongs to the class of organic compounds known as ubiquinones. These are coenzyme Q derivatives containing a 5, 6-dimethoxy-3-methyl(1,4-benzoquinone) moiety to which an isoprenyl group is attached at ring position 2(or 6).
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Quinone and hydroquinone lipids
Direct Parent
Ubiquinones
Alternative Parents
Polyterpenoids / Polyprenylbenzoquinones / P-benzoquinones / Vinylogous esters / Organic oxides / Hydrocarbon derivatives
Substituents
Polyterpenoid / Polyprenylbenzoquinone / Ubiquinone skeleton / Quinone / P-benzoquinone / Vinylogous ester / Cyclic ketone / Ketone / Organic oxygen compound / Organic oxide
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
ubiquinones (CHEBI:46245) / ubiquinones, Coenzymes (C11378) / Ubiquinones (LMPR02010001)

Drug created on October 28, 2015 09:41 / Updated on October 21, 2017 19:33